美国 · SEC FORM 4
Wave Life Sciences Ltd.
WVE · Nasdaq · CIK 0001631574 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
13 同一窗口内观察到的 Form 4 交易行
4 sales · 9 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-30 · Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 18,556,315
- 上期报告
- 17,637,783
- 日均成交量
- 3,255,781
- 回补天数
- 5.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-30 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 971,091 | USD 6.50 | USD 6,312,092 | SEC 申报 ↗ |
| 2026-03-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 2,495,623 | USD 6.43 | USD 16,046,856 | SEC 申报 ↗ |
| 2026-03-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 5,305,782 | USD 6.08 | USD 32,265,431 | SEC 申报 ↗ |
| 2025-12-11 | GSK plc | 买入 (P) | Ordinary Shares | 1,470,000 | USD 19.00 | USD 27,930,000 | SEC 申报 ↗ |
| 2025-11-13 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 1,000 | USD 6.69 | USD 6,690 | SEC 申报 ↗ |
| 2024-09-27 | GSK plc | 买入 (P) | Ordinary Shares | 2,791,930 | USD 8.00 | USD 22,335,440 | SEC 申报 ↗ |
| 2023-12-11 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 1,000,000 | USD 5.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2023-12-11 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Common Stock | 1,000,000 | USD 5.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2023-12-07 | GSK plc | 买入 (P) | Ordinary Shares | 3,300,000 | USD 5.00 | USD 16,500,000 | SEC 申报 ↗ |
| 2022-06-16 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 9,480,052 | USD 2.15 | USD 20,382,112 | SEC 申报 ↗ |
Form 4 申报证据
92 transaction lines in the latest 365-day window; 198 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Wagner Heidi L | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Verdine Gregory L. | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Tan Aik Na | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Wagner Heidi L | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Verdine Gregory L. | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Tan Aik Na | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | TAKANASHI KEN | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Rawcliffe Adrian | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | HENRY CHRISTIAN O | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-10-05 | CORRIGAN MARK | 奖励／授予 (A) | Common Stock | 10,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-12 | Rawcliffe Adrian | 卖出 (S) | Common Stock | 12,700 | USD 5.29 | USD 67,183 | SEC 申报 ↗ |
| 2026-08-11 | Wagner Heidi L | 卖出 (S) | Common Stock | 7,000 | USD 6.01 | USD 42,070 | SEC 申报 ↗ |
| 2026-08-11 | Wagner Heidi L | 期权行权／转换 (M) | Common Stock | 7,000 | USD 5.97 | USD 41,790 | SEC 申报 ↗ |
| 2026-08-11 | Tan Aik Na | 卖出 (S) | Common Stock | 432 | USD 6.01 | USD 2,596 | SEC 申报 ↗ |
| 2026-08-11 | TAKANASHI KEN | 卖出 (S) | Common Stock | 3,864 | USD 6.01 | USD 23,223 | SEC 申报 ↗ |
| 2026-03-30 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 971,091 | USD 6.50 | USD 6,312,092 | SEC 申报 ↗ |
| 2026-03-27 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 2,495,623 | USD 6.43 | USD 16,046,856 | SEC 申报 ↗ |
| 2026-03-26 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M. | 买入 (P) | Ordinary Shares | 5,305,782 | USD 6.08 | USD 32,265,431 | SEC 申报 ↗ |
| 2026-03-23 | TAKANASHI KEN | C (C) | Ordinary Shares | 3,901,348 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-26 | Francis Chris | 卖出 (S) | Ordinary Shares | 33,194 | USD 15.05 | USD 499,521 | SEC 申报 ↗ |
| 2026-02-26 | Francis Chris | 期权行权／转换 (M) | Ordinary Shares | 33,194 | USD 4.28 | USD 141,920 | SEC 申报 ↗ |
| 2026-02-09 | Vargeese Chandra | 卖出 (S) | Ordinary Shares | 3,228 | USD 13.45 | USD 43,417 | SEC 申报 ↗ |
| 2026-02-09 | Moran Kyle | 卖出 (S) | Ordinary Shares | 3,588 | USD 13.45 | USD 48,259 | SEC 申报 ↗ |
| 2026-02-09 | Francis Chris | 卖出 (S) | Ordinary Shares | 1,883 | USD 13.45 | USD 25,326 | SEC 申报 ↗ |
| 2026-02-09 | BOLNO PAUL | 卖出 (S) | Ordinary Shares | 10,480 | USD 13.45 | USD 140,956 | SEC 申报 ↗ |
| 2026-02-05 | Vargeese Chandra | 奖励／授予 (A) | Ordinary Shares | 45,625 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-05 | Moran Kyle | 奖励／授予 (A) | Ordinary Shares | 45,625 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-05 | Francis Chris | 奖励／授予 (A) | Ordinary Shares | 38,750 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-05 | BOLNO PAUL | 奖励／授予 (A) | Ordinary Shares | 165,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-02 | Francis Chris | 卖出 (S) | Ordinary Shares | 9,375 | USD 16.03 | USD 150,260 | SEC 申报 ↗ |
| 2026-01-02 | Francis Chris | 期权行权／转换 (M) | Ordinary Shares | 9,375 | USD 3.14 | USD 29,438 | SEC 申报 ↗ |
| 2025-12-11 | GSK plc | 买入 (P) | Ordinary Shares | 1,470,000 | USD 19.00 | USD 27,930,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | WVE |
| CIK | 0001631574 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 198 transaction lines from 2020-02-03 to 2026-10-05 11 P purchase lines · 97 S sale lines · 90 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.